Restricting patients' medication supply to one month: Saving or wasting money?

American Journal of Health-System Pharmacy

Volumn 61, Issue 13, 2004, Pages 1375-1379

  Domino, Marisa Elena ^a   Olinick, Joshua ^a   Sleath, Betsy ^b   Leinwand, Sharman ^c   Byrns, Patricia J ^d   Carey, Tim ^d  

^a IL   (United States)

^b University of North Carolina   (United States)

^c NORTH CAROLINA DEPARTMENT OF HEALTH AND HUMAN SERVICES   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Administration; Angiotensin converting enzyme inhibitors; Antidepressants; Antiinflammatory agents; Antipsychotic agents; Dispensing; Economics; Gastrointestinal drugs; Health benefit programs; Medication orders; Prescriptions; Protocols; Sulfonylureas; Wastage

Indexed keywords

ANTIULCER AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; SEROTONIN UPTAKE INHIBITOR; SULFONYLUREA; DRUG;

ARTICLE; DRUG COST; HEALTH CARE COST; HEALTH CARE FINANCING; HEALTH CARE POLICY; HEALTH INSURANCE; PRESCRIPTION; PRIORITY JOURNAL; COST CONTROL; ECONOMICS; HEALTH CARE QUALITY; HUMAN; MEDICAID; METHODOLOGY; UNITED STATES;

COST SAVINGS; DRUG COSTS; HUMANS; MEDICAID; NORTH CAROLINA; PHARMACEUTICAL PREPARATIONS; PROGRAM EVALUATION;

EID: 5144226998     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/61.13.1375     Document Type: Article

References (19)

1. Centers for Medicare and Medicaid Services. Table 2: national health expenditures aggregate amounts and average annual percent change, by type of expenditure: selected calendar years 1980-2001. http://cms.hhs.gov/statistics/ nhe/ historical/t2.asp? (accessed 2003 May 21).
2. Caffrey A, Hensley S, Gold R. States go to court in bid to rein in price of Medicaid. Wall Street J. 2002; May 21:A1.
3. Office of the Inspector General. Medicaid pharmacy - actual acquisition cost of brand name prescription drug products. http://oig.hhs.gov/oas/reports/ region6/ 60000023.pdf (accessed 2002 Dec 3).
4. North Carolina Department of Health and Human Services. Medicaid in North Carolina annual report, state fiscal year 2001. www.dhhs.state.nc.us/dma/ 2001report/annualreport.pdf (accessed 2002 Dec 3).
5. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998; 317:703-13. [Erratum, BMJ. 1999; 318:29.]
6. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352:837-53.
7. Brown JB, Nichols GA, Glauber HS et al. Health care costs associated with escalation of drug treatment in type 2 diabetes mellitus. Am J Health-Syst Pharm. 2001; 58:151-7.
8. Coombs JH, Cornish L, Hiller P et al. Compliance and refill pattern behavior with HMG-CoA reductase inhibitors after acute myocardial infarction. Manag Care Interface. 2002; 15:54-8,60.
9. Centers for Medicare and Medicaid Services. Medicaid managed penetration rates by state, June 30, 2002 - national summary table. www.cms.hhs.gov/ medicaid/managedcare/mcsten02.pdf (accessed 2003 May 21).
10. The Lewin Group, with assistance from West Virginia Medical Institute. The Lewin Group North Carolina Medicaid Benefits Study. Prepared for the North Carolina General Assembly. 2001 May 1.
11. North Carolina Senate Bill 1005, §21. 26(b).
12. North Carolina Department of Health and Human Services. North Carolina Medicaid DMA pharmacy newsletter, July 2001. www.dhhs.state.nc.us/dma/ pharmnews/0701pharm.pdf (accessed 2002 Jan 7).
13. Parikh SP, Dishman BR, Smith TL. Ninety-day versus thirty-day drug-dispensing systems. Am J Health-Syst Pharm. 2001; 58:1190-1.
14. Wallon SM, Arondekar BA, Johnson NE et al. A model for comparing unnecessary costs associated with various prescription fill-quantity policies: illustration using VA data. Am J Manag Care Pharm. 2001; 7:386-90.
15. Levy RA. Failure to refill prescriptions: incidence, reasons, and remedies. In: Cramer JA, Spilker B, eds. Patient compliance in medical practice. New York: Raven Press; 1991:11-8.
16. Wyeth-Ayerst prescription drug benefit cost and plan design survey report. Philadelphia:Wyeth-Ayerst; 1999.
17. National Consumers League. Consumer guide to generic drugs. www.nclnet.org/ Generics.pdf (accessed 2002 Aug 29).
18. North Carolina Department of Health and Human Services. North Carolina Medicaid pharmacy newsletter, June 2003. www.dhhs.state.nc.us/dma/ pharmnews/0603pharm.pdf (accessed 2003 Sep 17).
19. Pharmacy benefit report. East Hanover, NJ: Novartis Pharmaceuticals; 2002.